Susana Pereira1, Filipa Fontes2, Teresa Sonin3, Teresa Dias3, Maria Fragoso3, José Castro-Lopes4, Nuno Lunet5. 1. Portuguese Institute of Oncology of Porto, Porto, Portugal; EPIUnit-Institute of Public Health, University of Porto (ISPUP), Porto, Portugal. 2. EPIUnit-Institute of Public Health, University of Porto (ISPUP), Porto, Portugal. 3. Portuguese Institute of Oncology of Porto, Porto, Portugal. 4. Department of Experimental Biology, Faculty of Medicine, University of Porto, Porto, Portugal; Institute for Molecular and Cell Biology (IBMC), University of Porto, Porto, Portugal. 5. EPIUnit-Institute of Public Health, University of Porto (ISPUP), Porto, Portugal; Department of Clinical Epidemiology, Predictive Medicine and Public Health, Faculty of Medicine, University of Porto, Porto, Portugal. Electronic address: nlunet@med.up.pt.
Abstract
CONTEXT: Neuropathic pain (NP) may be an important contributor to the morbidity burden of breast cancer. OBJECTIVES: We aimed to quantify the incidence of NP in the first year after diagnosis of breast cancer and to identify its main determinants. METHODS: We performed a prospective cohort study including 506 patients with incident breast cancer, recruited at the Portuguese Institute of Oncology of Porto, and followed for one year; patients with incident NP were additionally evaluated when this condition was diagnosed and after six months, to identify chronic NP. RESULTS: During the first year, 156 patients were diagnosed with NP (30.8%, 95% CI 27.0-35.0). Anxiety (relative risk [RR] 1.50; 95% CI 1.06-2.13), arm symptoms (RR 1.44; 95% CI 1.02-2.05), cancer Stage III/IV (RR 2.47; 95% CI 1.66-3.66), breast-conserving surgery with axillary lymph node dissection (RR 3.13; 95% CI 1.51-6.48), mastectomy with axillary lymph node dissection (RR 2.52; 95% CI 1.25-5.11), and damaging of the intercostobrachial nerve (RR 2.05; 95% CI 1.25-3.37) were predictors of a higher risk of NP. A total of 97 patients (62.2%, 95% CI 54.4-69.4) diagnosed with NP remained symptomatic after six months. CONCLUSION: NP and chronic NP were frequent in this population, being associated with anxiety and arm symptoms before breast cancer treatments and type of surgical management. These results highlight the need for monitoring the occurrence of this neurologic side effect of treatments and to develop strategies for reducing the morbidity burden of breast cancer.
CONTEXT: Neuropathic pain (NP) may be an important contributor to the morbidity burden of breast cancer. OBJECTIVES: We aimed to quantify the incidence of NP in the first year after diagnosis of breast cancer and to identify its main determinants. METHODS: We performed a prospective cohort study including 506 patients with incident breast cancer, recruited at the Portuguese Institute of Oncology of Porto, and followed for one year; patients with incident NP were additionally evaluated when this condition was diagnosed and after six months, to identify chronic NP. RESULTS: During the first year, 156 patients were diagnosed with NP (30.8%, 95% CI 27.0-35.0). Anxiety (relative risk [RR] 1.50; 95% CI 1.06-2.13), arm symptoms (RR 1.44; 95% CI 1.02-2.05), cancer Stage III/IV (RR 2.47; 95% CI 1.66-3.66), breast-conserving surgery with axillary lymph node dissection (RR 3.13; 95% CI 1.51-6.48), mastectomy with axillary lymph node dissection (RR 2.52; 95% CI 1.25-5.11), and damaging of the intercostobrachial nerve (RR 2.05; 95% CI 1.25-3.37) were predictors of a higher risk of NP. A total of 97 patients (62.2%, 95% CI 54.4-69.4) diagnosed with NP remained symptomatic after six months. CONCLUSION: NP and chronic NP were frequent in this population, being associated with anxiety and arm symptoms before breast cancer treatments and type of surgical management. These results highlight the need for monitoring the occurrence of this neurologic side effect of treatments and to develop strategies for reducing the morbidity burden of breast cancer.
Authors: Kristin L Schreiber; Nantthansorn Zinboonyahgoon; K Mikayla Flowers; Valerie Hruschak; Kara G Fields; Megan E Patton; Emily Schwartz; Desiree Azizoddin; Mieke Soens; Tari King; Ann Partridge; Andrea Pusic; Mehra Golshan; Rob R Edwards Journal: Ann Surg Oncol Date: 2021-01-15 Impact factor: 5.344
Authors: Ivana Leao Ribeiro; Ximena Gálvez González; Diego Lara Torres; Luz Alejandra Lorca; Snehil Dixit; Nicolás Yáñez Benavides; Francisco Ortega Gonzalez Journal: Int J Breast Cancer Date: 2021-10-18
Authors: Laura Lorenzo-Gallego; Beatriz Arranz-Martín; Helena Romay-Barrero; Virginia Prieto-Gómez; Enrique Lluch; María Torres-Lacomba Journal: Int J Environ Res Public Health Date: 2022-03-29 Impact factor: 3.390
Authors: Anne Lukas; Maurice Theunissen; Dianne de Korte-de Boer; Sander van Kuijk; Lotte Van Noyen; Walter Magerl; Werner Mess; Wolfgang Buhre; Madelon Peters Journal: Trials Date: 2022-07-25 Impact factor: 2.728